Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
search
Join
FREE
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
Join
FREE
Filter Content:
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Videos
Oncology
19 Nov 2015
Physical activity levels and barriers to exercise referral among patients with cancer
Dorothy Yang gives an overview of a study assessing the physical activity levels and barriers to exercise referral among patients with cancer, at the…
Oncology
19 Nov 2015
2015 NCRI Cancer Conference: Featured sessions
Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research Institute, London, UK, gives an overview of the…
Oncology
19 Nov 2015
2015 NCRI Cancer Conference: The highlights
Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research Institute, London, UK, gives an overview of the…
Oncology
19 Nov 2015
Current status and future prospective of Trial Assigning IndividuaLized Options for Treatment (Rx)
At the European Cancer Congress (ECC) 2015, André Robidoux, MD, FRCSC, of Centre Hospitalier de l’Université de Montréal, Montreal, Canada, discusses…
Oncology
23 Oct 2015
Results and impact of TAILORx: Trial Assigning IndividuaLized Options for Treatment (Rx)
At the European Cancer Congress (ECC) 2015, André Robidoux, MD, FRCSC, of Centre Hospitalier de l’Université de Montréal, Montreal, Canada, discusses…
Oncology
23 Oct 2015
Immunotherapy: Targeting tumour heterogeneity
At the European Cancer Congress (ECC) 2015, Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research…
Oncology
15 Oct 2015
New approaches to molecular cancer therapeutics
At the European Cancer Congress (ECC) 2015, Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research…
Oncology
15 Oct 2015
The Patient Reported Opinions about Clinical Tolerability (PROACT)
At the European Cancer Congress (ECC) 2015, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute UK, London, UK, discusses Patient…
Oncology
15 Oct 2015
EURECCA international comparison of treatment patterns for non-metastatic breast cancer
At the European Cancer Congress (ECC) 2015, Riccardo A. Audisio, MD, FRCS, of the University of Liverpool, St. Helens Teaching Hospital, St. Helens, UK…
Oncology
15 Oct 2015
Results from the ETOP Lungscape Project: Multiplex mutation testing in NSCLC
At the European Cancer Congress (ECC) 2015, Keith M. Kerr, BSc, MB, ChB, FRCPath, FRCPE, of the University of Aberdeen, Aberdeen, Scotland, discusses the…
Oncology
15 Oct 2015
The causes and consequences of tumour evolution and heterogeneity
At the European Cancer Congress (ECC) 2015, Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research…
Oncology
15 Oct 2015
Patient-centered partnership improve access to optimal standards of cancer care in Europe
European Cancer Patient Coalition (ECPC) is the largest European cancer patients’ umbrella organisation, representing 365 patient organisations in 40…
Oncology
15 Oct 2015
ECC 2015: Press programme with updates on ‘Europe of Disparities in Cancer’
At the European Cancer Congress (ECC) 2015, Mark Lawler, PhD, of Queen’s University Belfast, Belfast, UK, Richard Sullivan, MD, PhD, of King’s College…
Oncology
15 Oct 2015
The discovery of new biomarkers for predicting outcomes in breast cancer
In patients with early stage breast cancer, there is a need to identify prognostic factors to determine the risk of recurrence and predictive factors to…
Oncology
15 Oct 2015
First-in-human study of first-in-class fatty acid synthase inhibitor, TVB-2640
At the European Cancer Congress (ECC) 2015, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute UK, London, UK, discusses a first-in…
Oncology
15 Oct 2015
Exploratory analysis of frontline therapies in REVEL: A phase 3 trial of ramucirumab in NSCLC
At the European Cancer Congress (ECC) 2015, Giorgio V. Scagliotti, MD, PhD, of the University of Turin, Turin, Italy, discusses the exploratory analysis…
Oncology
15 Oct 2015
ECC 2015: News briefing chaired by Prof Peter Naredi
At the European Cancer Congress (ECC) 2015, Peter Naredi, MD, PhD, of the University of Gothenburg, Gothenburg, Sweden, chairs a news briefing with…
Oncology
15 Oct 2015
Phase 2 trial of TAK-385, an oral GnRH antagonist, in prostate cancer
At the European Cancer Congress (ECC) 2015, Neal Shore, MD, FACS, of Carolina Urologic Research Center, Myrtle Beach, SC, discusses the first interim…
Oncology
15 Oct 2015
ECC 2015: Cancer healthcare inequalities between and within countries in Europe
There is a growing divide in cancer healthcare and survivorship between populations across Europe. European Cancer Patient Coalition (ECPC), the largest…
Oncology
15 Oct 2015
TAILORx: Prospective phase 3 trial validating a 21-gene expression assay in breast cancer
At the European Cancer Congress (ECC) 2015, Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, New York, NY, discusses the low-risk…
Oncology
15 Oct 2015
ECC 2015: Challenging the European disparities in cancer care
European Cancer Patient Coalition (ECPC), the largest European cancer patients’ umbrella organisation, presented the paper, ‘Europe of Disparities in…
Oncology
15 Oct 2015
ECC 2015: Hormonal therapy may prevent ovarian failure and preserve fertility in breast cancer
A meta-analysis was conducted to include 12 randomised trials and a total of 1,231 breast cancer patients receiving chemotherapy, with or without…
Oncology
15 Oct 2015
Clinical access to genomic information in Europe
Genomic interventions may improve disease-risk stratification and patient-tailored treatment. At the European Cancer Congress (ECC) 2015, John Crown, MD…
Oncology
14 Oct 2015
Results and impact of TAILORx: Trial Assigning IndividuaLized Options for Treatment (Rx)
At the European Cancer Congress (ECC) 2015, John Crown, MD, MBA, of St Vincent’s University Hospital, Dublin, Ireland, discusses the low-risk registry…
Oncology
14 Oct 2015
Phase 1b trial of avelumab in advanced gastric or gastroesophageal junction cancer
At the European Cancer Congress (ECC) 2015, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute UK, London, UK, discusses a phase 1b…
Oncology
14 Oct 2015
ECC 2015: Post-diagnosis aspirin improves survival in gastrointestinal cancers
Results from a study in The Netherlands involving 13,715 patients showed that aspirin use after a cancer diagnosis significantly improved overall…
Oncology
14 Oct 2015
ECC 2015: New survival data from Combi-v trial of combination of two targeted therapies in melanoma
Updated results from the phase 3 COMBI-v trial of a combination of dabrafenib and trametinib for the first-line treatment of patients with…
Oncology
14 Oct 2015
ECC 2015: NETTER-1 trial showed rare cancer responded unusually well to new treatment
NETTER-1, a phase 3 clinical trial, evaluated Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in patients with Grade 1–2 metastatic…
Oncology
14 Oct 2015
ECC 2015: RADIANT-4 trial showed promise in the treatment of neuroendocrine tumours
RADIANT-4, a placebo-controlled, double-blind, phase 3 clinical trial conducted in centres in 13 European countries, Korea, Japan, Canada, and the US…
Oncology
14 Oct 2015
ECC 2015: Launch of the European Society for Paediatric Oncology (SIOPE) strategic plan
The European Society for Paediatric Oncology (SIOP Europe or SIOPE), is a pan-European organisation that represents professionals working in the field…
Oncology
14 Oct 2015
ECC 2015: News briefing chaired by Prof Martine Piccart
At the European Cancer Congress (ECC) 2015, Martine Piccart, MD, PhD, of Université Libre de Bruxelles and Institut Jules Bordet, Brussels, Belgium…
Oncology
14 Oct 2015
ECC 2015: CheckMate 025 trial showed nivolumab improved overall survival in advanced kidney cancer
CheckMate 025, a phase 3 clinical trial, compared the anti-programmed cell death protein-1 (PD-1) antibody, nivolumab, with the standard treatment…
Oncology
14 Oct 2015
ECC 2015: EUROCARE-5 trial showed large variations in blood cancer survival in Europe
Comparisons of cancer patients’ survival and care in Europe up to 2007 showed that although more patients are surviving for at least five years after…
Oncology
14 Oct 2015
ECC 2015: METEOR trial showed cabozantinib improved survival in advanced kidney cancer
METEOR, a phase 3 clinical trial, compared cabozantinib with everolimus for the treatment of patients with advanced clear cell renal cell carcinoma.
Oncology
14 Oct 2015
The value of an intermediate Recurrence Score® result in the Oncotype DX® Breast Cancer Assay
The Oncotype DX® Breast Cancer Assay is a 21-gene assay that provides a Recurrence Score® (RS), which is divided into low-, intermediate- and high-risk…
Oncology
14 Oct 2015
TERRAIN trial of enzalutamide versus bicalutamide for advanced prostate cancer
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC…
Oncology
14 Oct 2015
Assessing the eligibility of a breast cancer patient for genomic testing
Genomic tests, such as the Oncotype DX® Breast Cancer Assay, provide results that quantify recurrence risk and identify patients who are likely or…
Oncology
14 Oct 2015
Updated results of a phase 1a study of anti-PDL1, MPDL3280A, in urothelial bladder cancer
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Thomas Powles, MBBS, MRCP, MD, of Barts Cancer Institute, Queen Mary University…
Oncology
14 Oct 2015
Experience of the Oncotype DX® Breast Cancer Assay in the clinic
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Harold J. Burstein, MD, PhD, of Dana-Farber Cancer Institute, Boston, MA…
Oncology
15 Sep 2015
Genomic testing for breast cancer in the neoadjuvant setting
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hope S. Rugo, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center…
Oncology
15 Sep 2015
Introducing the Oncotype DX® Breast Cancer Assay and its impact in clinical practice
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Mohammed Jaloudi, MD, of Tawam Hospital, Al Ain, United Arab Emirates, discusses…
Oncology
15 Sep 2015
The use of Ki-67, a proliferation marker, for guiding treatment decisions in breast cancer patients
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph Gligorov, MD, PhD, of Sorbonne Université, Paris, France, discusses some…
Oncology
15 Sep 2015
Introducing the Oncotype DX® Breast Cancer Assay in the clinic
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Harold J. Burstein, MD, PhD, of Dana-Farber Cancer Institute, Boston, MA…
Oncology
15 Sep 2015
Refining the therapeutic approach for breast cancer through genomic profiling
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Mohammed Jaloudi, MD, of Tawam Hospital, Al Ain, United Arab Emirates, discusses…
Oncology
15 Sep 2015
Considerations when selecting a genomic test to use in specific breast cancer patients
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hope S. Rugo, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center…
Oncology
9 Sep 2015
Genomic profiling for defining luminal subtypes
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Harold J. Burstein, MD, PhD, of Dana-Farber Cancer Institute, Boston, MA…
Oncology
9 Sep 2015
Using genomic testing to access the suitability of breast cancer patients for chemotherapy
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph Gligorov, MD, PhD, of Sorbonne Université, Paris, France, discusses the…
Oncology
26 Aug 2015
Registry evaluating the impact of genomic testing on treatment of prostate cancer patients
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, discusses…
Oncology
26 Aug 2015
CancerLinQ: ASCO’s initiative to improve patient care through big data
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, Omaha, NE…
Oncology
26 Aug 2015
ARAMIS trial of ODM-201 for high-risk non-metastatic castration-resistant prostate cancer
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, discusses…
Oncology
26 Aug 2015
Immune checkpoint inhibitors and biomarker-driven strategies for managing lung cancer
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Keith Kerr, BSc, MB, ChB, FRCPath, FRCPE, of the University of Aberdeen…
Oncology
26 Aug 2015
An update on the treatment of chronic lymphocytic leukaemia
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Stephan Stilgenbauer, MD, of Ulm University, Ulm, Germany, reviews the changing…
Oncology
26 Aug 2015
HELIOS: Phase 3 trial of ibrutinib with bendamustine and rituximab for relapsed/refractory CLL
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jacqueline Barrientos, MD, of North Shore-LIJ Cancer Institute, Lake Success, NY…
Oncology
26 Aug 2015
IMAAGEN: Phase 2 trial of abiraterone acetate for advanced prostate cancer
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, provides…
Oncology
26 Aug 2015
CheckMate 067: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Paolo A. Ascierto, MD, of Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale…
Oncology
26 Aug 2015
The evolving role of chemotherapy for the management of advanced prostate cancer
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Karim Fizazi, MD, PhD, of the Institut Gustave Roussy, Villejuif, France…
Oncology
26 Aug 2015
Daratumumab for heavily pretreated multiple myeloma
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sagar Lonial, MD, of the Winship Cancer Institute, Emory University, Atlanta…
Oncology
26 Aug 2015
Current clinical perspectives on targeted therapy and immunotherapy for melanoma
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Caroline Robert, MD, PhD, of Institut Gustave Roussy, Villejuif, France…
Oncology
26 Aug 2015
ENDEAVOR: Phase 3 trial comparing carfilzomib versus bortezomib in relapsed multiple myeloma
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph R. Mikhael, MD, of Mayo Clinic, Scottsdale, AZ, discusses the…
Oncology
26 Aug 2015
Phase 2 trial of lenvatinib and everolimus for metastatic renal cell carcinoma
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sumanta K. Pal, MD, of City of Hope Comprehensive Cancer Center, Duarte, CA…
Oncology
26 Aug 2015
Frontline and relapsed treatment of follicular lymphoma
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting Jeremy S. Abramson, MD, of the Massachusetts General Hospital Cancer Center…
Oncology
26 Aug 2015
The Conquer Cancer Foundation of the American Society of Clinical Oncology
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center…
Oncology
26 Aug 2015
Evaluating sustained adherence to ibrutinib in previously treated CLL
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jacqueline Barrientos, MD, of North Shore-LIJ Cancer Institute, Lake Success…
Oncology
21 Aug 2015
Therapy for newly diagnosed patients with mantle cell lymphoma
At the 20th Congress of the European Hematology Association (EHA), Marek Trněný, MD, PhD, of Charles University, Prague, Czech Republic, discusses new…
Loading posts...
« Previous
1
…
70
71
72
73
74
…
90
Next »
We’ve noticed you’re accessing
from
North/South America.
View
View